PMID- 37978564
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231124
IS  - 1710-1484 (Print)
IS  - 1710-1492 (Electronic)
IS  - 1710-1484 (Linking)
VI  - 19
IP  - 1
DP  - 2023 Nov 17
TI  - Helicobacter pylori infection attenuates 2,4-dinitrochlorobenzene-induced atopic 
      dermatitis-like skin lesions in C57/BL6 mice.
PG  - 97
LID - 10.1186/s13223-023-00851-x [doi]
LID - 97
AB  - BACKGROUND: Although numerous studies have suggested a negative correlation 
      between Helicobacter pylori (H. pylori) infection and allergies, there has been 
      limited research on the relationship between H. pylori infections and atopic 
      dermatitis (AD). The present study aimed to investigate the effects of H. pylori 
      infection in an AD mouse model and identify potential mechanisms related to type 
      2 immunity, skin barrier defects, and pruritus. METHODS: A model of AD-like 
      symptoms was established with 2,4-dinitrochlorobenzene (DNCB) after infection of 
      the gastric cavity with H. pylori. Analysis of the expression of key inflammatory 
      cytokines and serum levels of immunoglobulin E (IgE) was based on enzyme-linked 
      immunosorbent assay (ELISA). The expression of filaggrin (FLG) and loricrin (LOR) 
      were analyzed by immunohistochemistry staining. The evaluation of STAT1, STAT3, 
      phosphorylated STAT1 (phospho-STAT1), and phosphorylated STAT3 (phospho-STAT1) 
      expression levels in skin lesions was performed using western blot. RESULTS: The 
      present study showed that the H. pylori-positive AD group (HP+AD+) exhibited 
      milder skin lesions, including erythema, erosion, swelling, and scaling, than the 
      H. pylori-negative AD group (HP-AD+). Additionally, HP+AD+ displayed lower levels 
      of IgE in serum, and downregulated expression of interleukins 4 and 31 (IL-4 and 
      IL-31) in serum. Furthermore, HP+AD+ demonstrated higher expression of filaggrin 
      and loricrin than HP-AD+. Notably, H. pylori significantly reduced the amount of 
      phosphorylated STAT1 and STAT3. CONCLUSION: Helicobacter pylori infection 
      negatively regulates the inflammatory response by affecting inflammatory factors 
      in the immune response, and repairs the defective epidermal barrier function. In 
      addition, H. pylori infection may reduce IL-31, thereby alleviating pruritus. 
      These effects may be associated with the inhibition of JAK-STAT signaling 
      activation.
CI  - (c) 2023. The Author(s).
FAU - Wang, Shuxian
AU  - Wang S
AD  - Department of Dermatology, Medical College, Yangzhou University, Yangzhou, China.
FAU - Wang, Xiaokang
AU  - Wang X
AD  - Department of Dermatology, Clinical Medical College, Yangzhou University, 
      Yangzhou, China.
FAU - Liu, Jiaqi
AU  - Liu J
AD  - Veterinary Medical College, Yangzhou University, Yangzhou, China.
FAU - Li, Yaqian
AU  - Li Y
AD  - Veterinary Medical College, Yangzhou University, Yangzhou, China.
FAU - Sun, Minghui
AU  - Sun M
AD  - Department of Dermatology, Medical College, Yangzhou University, Yangzhou, China.
FAU - Zhu, Guoqiang
AU  - Zhu G
AD  - Veterinary Medical College, Yangzhou University, Yangzhou, China.
FAU - Zhu, Xiaofang
AU  - Zhu X
AD  - Department of Dermatology, Clinical Medical College, Yangzhou University, 
      Yangzhou, China. sharonzhu66@126.com.
LA  - eng
GR  - YZ2018065/YangZhou Science and Technology Bureau/
PT  - Journal Article
DEP - 20231117
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian 
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC10656826
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Helicobacter pylori
OT  - JAK-STAT
OT  - Pruritus
OT  - Skin barrier
COIS- The authors declared no competing interests.
EDAT- 2023/11/18 11:42
MHDA- 2023/11/18 11:43
PMCR- 2023/11/17
CRDT- 2023/11/18 03:21
PHST- 2023/05/27 00:00 [received]
PHST- 2023/10/23 00:00 [accepted]
PHST- 2023/11/18 11:43 [medline]
PHST- 2023/11/18 11:42 [pubmed]
PHST- 2023/11/18 03:21 [entrez]
PHST- 2023/11/17 00:00 [pmc-release]
AID - 10.1186/s13223-023-00851-x [pii]
AID - 851 [pii]
AID - 10.1186/s13223-023-00851-x [doi]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2023 Nov 17;19(1):97. doi: 
      10.1186/s13223-023-00851-x.